“Global Antibiotic Drugs market set to grow to $43.8bn by 2022” says Visiongain analyst

18 June 2018
Pharma

Visiongain’ has launched a new pharma report Top 25 Antibiotic Drugs Manufacturers 2018: US, Europe, Japan, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Others

The development of antibacterial resistance has created an opportunity for the drug industry as new anti-infectives are constantly required to target resistant organisms. Currently, a major opportunity lies in the development of drugs required for the treatment of hospital acquired infections and are associated with increased mortality and morbidity. Hence, most of the pharmaceutical companies are recommended to develop combination products to broaden the antibacterial spectrum of activity for combating bacterial resistance.

The lead analyst of the report commented: “Asia-Pacific and RoW are the fastest growing regional markets in the global antibacterial drugs market. Therefore, companies looking to accelerate their overall growth are recommended to invest in these emerging economies and to exploit the untapped growth opportunities available there. Companies are recommended to invest in emerging nations such as India and China, to capitalize on the opportunities available in the form of unmet medical needs, rising disposable incomes of the consumers and increased exposure to improved healthcare facilities.”

Leading companies featured in the report include Pfizer Inc., Merck & Co., Novartis, GSK, Bayer AG, Allergan plc, Shionogi & Co., Ltd., Taisho Pharmaceutical Holdings, Daiichi Sankyo, Sun Pharmaceutical Industries

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever